Alcon AG is primarily active in the healthcare and pharmaceutical industries.

The main competitors of Alcon AG in the market are Johnson & Johnson Vision, Bausch Health Companies Inc., and Novartis AG.

Alcon AG is a renowned company with a rich history and background. Established in XYZ, Alcon AG has become a leading player in the industry. The company specializes in XYZ products and services, catering to a wide range of customers worldwide. Over the years, Alcon AG has achieved significant milestones and global recognition for its innovative solutions and exceptional quality. With a strong commitment to excellence, Alcon AG continues to expand its presence and investment in research and development. With a solid track record, Alcon AG has remained a trusted choice for investors seeking growth and reliability in the market.

Alcon AG, a renowned stock, has achieved significant milestones throughout its journey. The company has successfully introduced groundbreaking products and technologies in the field of eye care. Alcon AG's major achievements include the development of revolutionary intraocular lenses (IOLs) that have enhanced vision correction and improved patients' quality of life. Additionally, the company pioneered innovative surgical equipment and techniques, such as advanced phacoemulsification devices, revolutionizing cataract surgery. Alcon AG has dedicated itself to providing cutting-edge ophthalmic solutions, elevating the standards of eye care globally. With its impressive track record, Alcon AG stands out as a leading entity within the stock market.

Alcon AG primarily operates in various countries and regions worldwide. With its global presence, the company has established a strong foothold in key markets across the Americas, Europe, Asia, and Africa. Alcon AG's extensive reach includes countries such as the United States, Germany, Switzerland, France, China, Japan, Australia, South Africa, and many others. The company's strategic expansion allows it to cater to a diverse clientele, providing innovative eye care products and services internationally.

Alcon AG represents a strong commitment to values and a clear corporate philosophy. The company prioritizes integrity, innovation, and excellence in all aspects of its operations. Alcon is dedicated to improving vision care and providing high-quality eye care products and services to its customers. With a focus on continuous research and development, Alcon aims to deliver cutting-edge solutions for eye health. By upholding these values and embracing a forward-thinking approach, Alcon AG sets itself apart as a trusted and leading player in the field of ophthalmic innovation.

Analysts currently set an average price target of 103,94 USD for the Alcon stock (median: 103,43 USD), implying +56,7 % versus the latest price. The consensus is based on 20 analyst ratings.

Alcon Koersdoelstellingen analisten 2026

20 analysts currently rate the Alcon stock: 16 recommend buying, 2 holding and 2 selling. For 2026, analysts expect Alcon to generate revenue of 10,97 Miljard USD and earnings per share of 3,45 USD.

Alcon Koersdoelstellingen analisten 2026

Converted at the current exchange rate, the Alcon share trades at 61,58 EUR (70,89 USD).

The Alcon share (ALC.SW) is listed on 7 stock exchanges, including: NYSE (ALC), Frankfurt (2U3.F), München (2U3.MU), Düsseldorf (2U3.DU), Hamburg (2U3.HM), London (0A0D.L), SIX (Zürich) (ALC.SW).

Alcon AG is a global company that offers a wide range of eye care products for patients and medical professionals. The company specializes in developing and manufacturing innovative solutions for optimal vision and eye health. Alcon operates in over 75 countries worldwide. Alcon has five main business areas: Surgery, Vision Care, Pharma, Ophthalmic Devices, and Ophthalmic Instruments. The Surgery division specializes in surgical procedures such as cataract surgery and retinal surgery. The Vision Care division deals with contact lenses, glasses, and other vision correction products. The Pharma division includes medications for treating eye diseases such as glaucoma and allergic conjunctivitis. The Ophthalmic Devices and Ophthalmic Instruments divisions specialize in medical accessories and instruments. Alcon's most well-known product is the Air Optix contact lens, available in various designs and materials, which allows for longer wear time. The Dailies contact lens line and the TrueTear therapy for dry eyes are also popular Alcon products. Alcon has also developed some innovative technologies, including the ORA System, which allows for more precise measurements of eye data during cataract surgery, and the WaveLight Refractive Suite for correcting refractive errors such as myopia, hyperopia, and astigmatism. Another important product from Alcon is Restasis, a medication for treating dry eyes. It is the first FDA-approved medication to stimulate natural tear production. Alcon's business model is based on innovation and quality. The company heavily invests in research and development to develop the eye care solutions of the future. Alcon also has a strong presence in the education and training of eye doctors and other medical professionals. The company offers training and continuing education to keep doctors and professionals up to date and help them utilize Alcon's innovative technologies and products. Alcon also has a strong online presence and offers a wide range of digital resources, including online training, resources for medical professionals and patients, and videos on eye care products and technologies. Overall, Alcon is a leading company in the eye care industry that focuses on innovation and quality. With a wide range of products and services and a strong presence in medical education and training, Alcon is well positioned to continue growing and improving eye health and vision worldwide.

De verwachte omzet van Alcon bedraagt 10,97 Miljard USD. Deze cijfers zijn gebaseerd op huidige financiële gegevens en weerspiegelen de bedrijfsresultaten van het bedrijf.

De verwachte winst van Alcon bedraagt 1,70 Miljard USD. De nettowinst weerspiegelt de rentabiliteit van het bedrijf na aftrek van alle kosten.

De koers-winstverhouding (P/E) van Alcon bedraagt momenteel 20,57. De P/E-ratio vergelijkt de huidige aandeelkoers met de winst per aandeel en helpt beleggers de waardering van het Alcon-aandeel in te schatten.

De koers-omzetverhouding (P/S) van Alcon bedraagt momenteel 3,18. De P/S-ratio vergelijkt de marktkapitalisatie met de jaarlijkse opbrengsten en dient als waarderingsmaatstaf voor het Alcon-aandeel.

De Eulerpool Kwaliteitsscore voor Alcon is 5/10.

De ISIN van Alcon is CH0432492467. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.

De WKN van Alcon is A2PDXE. De WKN (Wertpapierkennnummer) is een zescijferig Duits identificatienummer voor wertpapieren.

Het tickersymbool van Alcon is ALC.SW. Onder dit beurstickersymbool wordt het Alcon-aandeel op de beurs verhandeld.

Binnen de laatste 12 maanden betaalde Alcon een dividend van 0,28 USD . Dit komt overeen met een dividendrendement van ongeveer 0,39 %. Voor de komende 12 maanden zal Alcon naar verwachting een dividend van 0,34 USD betalen.

De dividendrendement van Alcon is momenteel 0,39 %.

Alcon betaalt een dividend uit, dat wordt uitgekeerd in de maanden , , , .

Alcon betaalde de afgelopen 5 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0,34 USD verwacht. Dit komt overeen met een dividendrendement van 0,51 %.

Alcon wordt toegewezen aan de sector 'Gezondheid'.

In het jaar 2025 heeft Alcon 0,48 USD aan dividenden uitgekeerd.

De dividenden van Alcon worden in USD uitgekeerd.